All News

RheumNow Podcast square

Pre-ACR25 (10.24.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and info reports the day before ACR 2025

Read Article
PMR2.jpg

REPLENISH - Secukinumab Works in Polymyalgia Rheumatica

Jack Cush, MD

Novartis announced the results of their REPLENISH trial showing the efficacy of secukinumab in adults with polymyalgia rheumatica (PMR).

Read Article
autoimmune.disease

SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease

Jack Cush, MD

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have benefits beyond glycemic control, including cardioprotective and nephroprotective effects, with modest weight loss.

Read Article
FDA%20approved2.jpg

FDA Approves Obinutuzumab for Active Lupus Nephritis

Jack Cush, MD

The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis.

Read Article
RheumNow Podcast square

Bad Actor Cofactor (10.17.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregnancy data, diet and nutrition and more.

Read Article
lupus_0.jpg

Telitacicept Effective in Systemic Lupus Erythematosus

Jack Cush, MD

The NEJM has published a report from van Vollenhoven et al showing a new dual B cell inhibitor, telitacicept, to be effective when given to active systemic lupus erythematosus (SLE) patients; but this comes with a few safety concerns.

Read Article
kneepain3.jpg (keep)

Arthritis Pain and Education Gaps Linked

EurekAlert!

New research from The University of Texas at Arlington shows that differences in state welfare policies are linked to rising arthritis-related joint pain across much of the U.S.

Read Article
pregnant, pregnancy, mother, fertility

Pregnancy Management in Inflammatory Bowel Disease: A Global Consensus

Jack Cush, MD

Consensus guidance on the management of pregnancy in patients with inflammatory bowel disease (IBD) was simultaneously published in six international journals, including The American Journal of Gastroenterology.

Read Article
RheumNow Podcast square

Eating Crow (10.10.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news, FDA approvals, and journal articles. In this episode: HMGCR Abs, FDA approvals and Cush eats crow.

Read Article
FDA has approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lupus nephritis who are receiving standard therapy. https://t.co/0eGwGnSDYf https://t.co/wnQDVnTEjb

Links:

Dr. John Cush RheumNow ( View Tweet)
Casal Moura, M., Merkel, P.A., Jayne, D. et al.Challenges in the diagnosis, classification and prognosis of ANCA-associated vasculitis. Nat Rev Rheumatol (2025). https://t.co/fGUr2DnfwA Good figure, citation above. Via @AKronbichler and colleagues https://t.co/FGfPFiGgMv

Links:

Suleman Bhana, MD DrBhana ( View Tweet)

Colchicine Ineffective in Long COVID Management of long COVID has been perplexing with symptoms having functional and possibly inflammatory origins. Colchicine has been studied in long COVID and failed to improve functional capacity, respiratory function, or inflammatory https://t.co/9E3dvUFqJP
Dr. John Cush RheumNow ( View Tweet)
FDA Approves Obinutuzumab for Active Lupus Nephritis The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis. https://t.co/WbpATY86BY https://t.co/zRONkCUtIx

Links:

Dr. John Cush RheumNow ( View Tweet)
Saphnelo (anifrolumab) has been recommended for approval in EU by CHMP for systemic lupus erythematosus (on top of standard therapy) as a once-weekly pre-filled pen. Recommendation based on TULIP-SC Phase III trial. https://t.co/VRUycfLRtf https://t.co/O7cQfkb8BU

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lupus nephritis who are receiving standard therapy. https://t.co/0eGwGnSDYf https://t.co/Z6w2iP4u3e

Links:

Dr. John Cush RheumNow ( View Tweet)
Failure of IL-17 inhibition in Lupus nephritis. 31 LN pts enrolled in phase 2 DBRPCT of secukinumab 300 mg IV, but was terminated early for futility (complete renal response at week 52 was lower with secukinumab (24.2%) than with placebo (36.3%). https://t.co/471TolqtFk https://t.co/gKi2Z2MZHS

Links:

Dr. John Cush RheumNow ( View Tweet)
Pregnancy Management in Inflammatory Bowel Disease: A Global Consensus Consensus guidance on the management of pregnancy in patients with inflammatory bowel disease (IBD) was simultaneously published in six international journals, including The American Journal of https://t.co/F6er2mpUoV
Dr. John Cush RheumNow ( View Tweet)
Tertiary center study of 147 GPA pts (age ~45, 18 mos F/U) - total of 55 deaths& 179 relapses (in 117 pts;1.53/pt). Predictors of relapse (~2 fold incr) = Age > 55, male, ^^creatinine & CNS dz. Mortality assoc w/ ≥ 55 yrs, male, creatinine >1.3, CNS @baseline https://t.co/GzScokrN7G
Dr. John Cush RheumNow ( View Tweet)
Eating Crow (10.10.2025) Dr. Jack Cush reviews the news, FDA approvals, and journal articles. In this episode: HMGCR Abs, FDA approvals and Cush eats crow. https://t.co/n5W8c7OeKS https://t.co/LXAxrE37WS

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved nerandomilast (PDE4b inhibitor) for treatment of adults with idiopathic pulmonary fibrosis (IPF). Approval is based on 2 RCTs, FIBRONEER-IPF & FIBRONEER-ILD, that show slowing of lung function decline IP & progressive pulmonary fibrosis (PPF) pts. https://t.co/pIQwyLUBoj
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×